anti-Ccr7 antibody product blog
Tags: Antibody; Polyclonal Antibody; CCR7; anti-CCR7 antibody; Chemokine CXCR7 receptor;
The CXCR7 ackr3 (Catalog #MBS540677) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The CXCR7 Antibody reacts with Human, Mouse, Rat and may cross-react with other species as described in the data sheet. MyBioSource\'s CXCR7 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunoprecipitation (IP), Western Blot (WB).Confocal Microscopy: 1:250
Immunocytochemistry: 1:250
Immunofluorescence: 1:250
Immunohistochemistry: 1:250
Immunoprecipitation: 1:250
Western Blot: 1:500. Researchers should empirically determine the suitability of the CXCR7 ackr3 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CXCR7 ackr3 product has the following accession number(s) (GI #22477173) (NCBI Accession #AAH36661) (Uniprot Accession #P25106). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Affinity Purified Chemokine (C-X-C motif) receptor 7 Antibody
Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival.
Immunogen: Synthetic peptide corresponding to unique amino acid sequence on human CXCR7 protein.
Expression: Expressed in monocytes, basophils, B-cells, umbilical vein endothelial cells (HUVEC) and B-lymphoblastoid cells. Lower expression detected in CD4+ T-lymphocytes and natural killer cells. In the brain, detected in endothelial cells and capillaries, and in mature neurons of the frontal cortex and hippocampus. Expressed in tubular formation in the kidney. Highly expressed in astroglial tumor endothelial, microglial and glioma cells. Expressed at low levels in normal CD34+ progenitor cells, but at very high levels in several myeloid malignant cell lines. Expressed in breast carcinomas but not in normal breast tissue. Molecular Function: Cell adhesion, Host-virus interaction
Structure: Homodimer. Can form heterodimers with CXCR4; heterodimerization may regulate CXCR4 signaling activity. Interacts with ARRB1 and ARRB2.
Subcellular Location: Cell membrane; Multi-pass membrane protein. Cytoplasm degree perinuclear region. Early endosome. Recycling endosome. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CXCR7 are readily searchable from our website. Different antibodies against the same target such as CXCR7 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.